Ances Beau M, Letendre Scott, Buzzell Maria, Marquie-Beck Jennifer, Lazaretto Deborah, Marcotte Thomas D, Grant Igor, Ellis Ronald J
Department of Neurosciences, University of California, San Diego, California, USA.
J Neurovirol. 2006 Oct;12(5):403-6. doi: 10.1080/13550280600981695.
Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.
丙戊酸（VPA）通过激活静息CD4+细胞来减少人类免疫缺陷病毒（HIV）潜伏库。这项回顾性病例对照研究（n = 30）考察了VPA对HIV进展标志物的影响。VPA与脑脊液病毒载量（VL）、血浆VL或神经心理学表现的变化无关。VPA患者在随访时CD4+细胞有降低的趋势（P = .08）。同时使用的抗逆转录病毒药物并未改变这些关系。VPA不会诱发病毒血症或促进疾病进展，可能对临床干预是安全的。
